Roche Reaffirms 2026 Outlook Despite Weak Vabysmo Sales, Strong Swiss Franc
Basel: Swiss drugmaker Roche confirmed its 2026 outlook on Thursday after first-half sales fell slightly in Swiss franc…
Roche contends with loss of momentum for key medicines, currency fluctuations in Q3 but keeps growth on track
Even as Roche executives on Thursday espoused confidence in the company’s resilience and growth potential over the next…
Roche Q1 earnings suffer blood bath thanks to currency headwinds
Editor’s Note: The original version of the story was based on consensus estimates cited by ODDO BHF. We’ve…
Roche to Present 46 Abstracts, 12 Orals at ASH Meeting
Roche (OTCQX: RHHBY) will present 46 abstracts, including 12 oral presentations, at ASH…